Cargando…

Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI

Selenium nanoparticle (SeNP)-based nanotherapeutics have become an emerging cancer therapy, while effective drug delivery remains a technical hurdle. A theranostic approach, through which imaging companions are integrated with SeNPs, will allow image-guided drug delivery and, therefore, is highly de...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Guanfu, Ling, Jiabao, He, Lizhen, Xu, Yuan, Chen, Tianfeng, Shi, Changzheng, Luo, Liangping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864256/
https://www.ncbi.nlm.nih.gov/pubmed/36678748
http://dx.doi.org/10.3390/pharmaceutics15010120
_version_ 1784875538311020544
author Liu, Guanfu
Ling, Jiabao
He, Lizhen
Xu, Yuan
Chen, Tianfeng
Shi, Changzheng
Luo, Liangping
author_facet Liu, Guanfu
Ling, Jiabao
He, Lizhen
Xu, Yuan
Chen, Tianfeng
Shi, Changzheng
Luo, Liangping
author_sort Liu, Guanfu
collection PubMed
description Selenium nanoparticle (SeNP)-based nanotherapeutics have become an emerging cancer therapy, while effective drug delivery remains a technical hurdle. A theranostic approach, through which imaging companions are integrated with SeNPs, will allow image-guided drug delivery and, therefore, is highly desirable. Traditional methods require the chemical conjugation of imaging agents to the surface of nanoparticles, which may impede the later clinical translation. In this study, we developed a label-free strategy in which lentinan-functionalized SeNPs (LNT-SeNPs) are detected using MRI by the hydroxyl protons carried on LNT molecules. The in vitro phantom study showed that LNT and LNT-SeNPs have a strong CEST signal at 1.0 ppm apart from the water resonance, suggesting an in vivo detectability in the µM concentration range. Demonstrated on CT26 colon tumor cells, LNT-SeNPs exert a strong anticancer effect (IC50 = 4.8 μM), prominently attributed to the ability to generate intracellular reactive oxygen species. However, when testing in a mouse model of CT26 tumors, administration of LNT-SeNPs alone was found unable to deliver sufficient drugs to the tumor, leading to poor treatment responses. To improve the drug delivery, we co-injected LNT-SeNPs and TNF-α, a previously reported drug that could effectively damage the endothelial cells in the tumor vasculature, thereby increasing drug delivery to the tumor. Our results revealed a 75% increase in the intratumoral CEST MRI signal, indicating a markedly increased delivery efficiency of LNT-SeNPs when combined with TNF-α. The combination therapy also resulted in a significantly enhanced treatment outcome, as revealed by the tumor growth study. Taken together, our study demonstrates the first label-free, SeNP-based theranostic system, in which LNT was used for both functional surface coating and CEST MRI signal generating. Such a theranostic LNT-SeNP system is advantageous because it requires chemical labeling and, therefore, has high biocompatibility and low translatable barriers.
format Online
Article
Text
id pubmed-9864256
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98642562023-01-22 Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI Liu, Guanfu Ling, Jiabao He, Lizhen Xu, Yuan Chen, Tianfeng Shi, Changzheng Luo, Liangping Pharmaceutics Article Selenium nanoparticle (SeNP)-based nanotherapeutics have become an emerging cancer therapy, while effective drug delivery remains a technical hurdle. A theranostic approach, through which imaging companions are integrated with SeNPs, will allow image-guided drug delivery and, therefore, is highly desirable. Traditional methods require the chemical conjugation of imaging agents to the surface of nanoparticles, which may impede the later clinical translation. In this study, we developed a label-free strategy in which lentinan-functionalized SeNPs (LNT-SeNPs) are detected using MRI by the hydroxyl protons carried on LNT molecules. The in vitro phantom study showed that LNT and LNT-SeNPs have a strong CEST signal at 1.0 ppm apart from the water resonance, suggesting an in vivo detectability in the µM concentration range. Demonstrated on CT26 colon tumor cells, LNT-SeNPs exert a strong anticancer effect (IC50 = 4.8 μM), prominently attributed to the ability to generate intracellular reactive oxygen species. However, when testing in a mouse model of CT26 tumors, administration of LNT-SeNPs alone was found unable to deliver sufficient drugs to the tumor, leading to poor treatment responses. To improve the drug delivery, we co-injected LNT-SeNPs and TNF-α, a previously reported drug that could effectively damage the endothelial cells in the tumor vasculature, thereby increasing drug delivery to the tumor. Our results revealed a 75% increase in the intratumoral CEST MRI signal, indicating a markedly increased delivery efficiency of LNT-SeNPs when combined with TNF-α. The combination therapy also resulted in a significantly enhanced treatment outcome, as revealed by the tumor growth study. Taken together, our study demonstrates the first label-free, SeNP-based theranostic system, in which LNT was used for both functional surface coating and CEST MRI signal generating. Such a theranostic LNT-SeNP system is advantageous because it requires chemical labeling and, therefore, has high biocompatibility and low translatable barriers. MDPI 2022-12-29 /pmc/articles/PMC9864256/ /pubmed/36678748 http://dx.doi.org/10.3390/pharmaceutics15010120 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Liu, Guanfu
Ling, Jiabao
He, Lizhen
Xu, Yuan
Chen, Tianfeng
Shi, Changzheng
Luo, Liangping
Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI
title Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI
title_full Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI
title_fullStr Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI
title_full_unstemmed Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI
title_short Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI
title_sort theranostic cancer treatment using lentinan-coated selenium nanoparticles and label-free cest mri
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864256/
https://www.ncbi.nlm.nih.gov/pubmed/36678748
http://dx.doi.org/10.3390/pharmaceutics15010120
work_keys_str_mv AT liuguanfu theranosticcancertreatmentusinglentinancoatedseleniumnanoparticlesandlabelfreecestmri
AT lingjiabao theranosticcancertreatmentusinglentinancoatedseleniumnanoparticlesandlabelfreecestmri
AT helizhen theranosticcancertreatmentusinglentinancoatedseleniumnanoparticlesandlabelfreecestmri
AT xuyuan theranosticcancertreatmentusinglentinancoatedseleniumnanoparticlesandlabelfreecestmri
AT chentianfeng theranosticcancertreatmentusinglentinancoatedseleniumnanoparticlesandlabelfreecestmri
AT shichangzheng theranosticcancertreatmentusinglentinancoatedseleniumnanoparticlesandlabelfreecestmri
AT luoliangping theranosticcancertreatmentusinglentinancoatedseleniumnanoparticlesandlabelfreecestmri